RARA and acute promyelocytic leukemia: ATRA targeting of the oncogenic PML–RARα fusion protein, together with the use of arsenic trioxide, has provided a cure for most patients with acute promyelocytic leukemia [4,7], but ATRA has failed to provide an effective treatment for other cancers [8,9,10,11].